Oncotarget

Meta-Analysis:

Efficacy of sorafenib in patients with hepatocellular carcinoma after resection: a meta-analysis

Jin Shang, Shanling Xu, Jiaxing Zhang, Xuting Ran, Lang Bai _ and Hong Tang

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:109723-109731. https://doi.org/10.18632/oncotarget.21299

Metrics: PDF 1230 views  |   HTML 2431 views  |   ?  


Abstract

Jin Shang1,*, Shanling Xu2,*, Jiaxing Zhang3, Xuting Ran4, Lang Bai1 and Hong Tang1

1Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan, China

2Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

3Chinese Evidence-based Medicine Center, Sichuan University, Chengdu, China

4West China Medical School, Sichuan University, Chengdu, Sichuan, China

*These authors contributed equally to this work and share Co-first authors

Correspondence to:

Lang Bai, email: [email protected]

Keywords: hepatocellular carcinoma, liver resection, sorafenib, overall survival, recurrence

Received: January 12, 2017     Accepted: September 13, 2017     Published: September 28, 2017

ABSTRACT

Background: The prognosis of hepatocellular carcinoma remains poor even after curative resection and it has no effective adjuvant therapy.

Aim: This meta-analysis aimed to assess efficacy of sorafenib as adjuvant therapy for patients with hepatocellular carcinoma after resection.

Materials and methods: A systematic search was conducted of Medline, Embase, Web of Science, Cochrane Library, Chinese Wanfang database, Chinese biological and medical database, China National Knowledgeand the Internet, data from 5 studies that included 296 participants were analyzed. The primary outcome was overall survival. Secondary outcomes included recurrence rate and mortality rate.

Results: In the comparison of sorafenib versus control, no significant difference in overall survival (hazard ratio 1.39, 95% confidence interval [CI] 0.71–2.74, P = 0.34) or recurrence rate [risk ratio (RR) 0.81, 95% CI; 0.65–1.01, P = 0.06) was found. For mortality rate, subgroup analysis was conducted according to study type, only in subgroup 2, the RR was significantly reduced (0.66, 95% CI; 0.51–0.87, P = 0.003) in studies.

Conclusions: In this meta-analysis, sorafenib achieves no significant benefit in any of the endpoints except a lower mortality rate in subgroup analysis, indicating that there is no convincing evidence of sorafenib as an effective adjuvant therapy in patients with hepatocellular carcinoma after resection.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21299